Atezolizumab for the treatment of breast cancer
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2020.1732211
Abstract: ABSTRACT Introduction: In March 2019, atezolizumab became the first immune checkpoint inhibitor to receive a breast cancer-specific approval. Based on a significant improvement in progression-free survival as well as a 10-month improvement in overall survival… read more here.
Keywords: cancer; atezolizumab treatment; breast cancer;
Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial
Sign Up to like & getrecommendations! Published in 2020 at "BMJ Open"
DOI: 10.1136/bmjopen-2019-035530
Abstract: Introduction Atezolizumab is a programmed death ligand-1 inhibitor for urothelial bladder cancer treatment. Atezolizumab has become the standard therapy for patients with urothelial bladder cancer who are not responding to cisplatin-based chemotherapy and is also… read more here.
Keywords: bladder cancer; trial; neoadjuvant atezolizumab; treatment ... See more keywords